Clinical and pharmacological group: & nbsp

Anxiolytics

Included in the formulation
  • Tranquesipam®
    solution w / m in / in 
    DALHIMFARM, OJSC     Russia
  • Tranquesipam®
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Fezaneff
    pills inwards 
    AKRIKHIN HFK, JSC     Russia
  • Phenazepam®
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Phenazepam®
    solution w / m in / in 
    VALENTA PHARM, PAO     Russia
  • Fenzitat®
    pills inwards 
  • Phenorelaxan®
    solution w / m in / in 
  • Phenorelaxan®
    pills inwards 
  • Elzepam®
    solution w / m in / in 
    ELLARA, LTD.     Russia
  • Elzepam®
    pills inwards 
    ELLARA, LTD.     Russia
  • АТХ:

    N.05.B.X   Other anxiolytics

    Pharmacodynamics:

    Benzodiazepine derivative of medium duration of action; causes depression of the central nervous system from mild sedation to coma, depending on the dose, enhanced effects of gamma-aminobutyric acid (GABA, the main inhibitory neurotransmitter central nervous system) by stronger binding to type A receptors (GABAA); agonist of benzodiazepine receptors known as benzodiazepine-GABAA-receptor-chloride-ionophore complex; located on the neural membrane, ion channel for Cl-; when GABA is activatedA-receptor opens the ion channel and the intake of Cl- in the neuron, a decrease in its excitability and a decrease in the effects of depolarizing excitatory transmitters.

    It has anxiolytic, anticonvulsant, central muscle relaxant and sedative-hypnotic (shortens the period of falling asleep, increases the duration of sleep, reduces the number of nocturnal awakenings) effects.

    Pharmacokinetics:

    After ingestion, it is well absorbed from the gastrointestinal tract. Metabolised in the liver. The half-life is 6-18 hours. It is excreted mainly by the kidneys in the form of metabolites.

    Indications:

    Neurotic, neurotic, psychopathic and psychopathic conditions, accompanied by fear, increased irritability, anxiety, tension and emotional lability; tik, athetosis and hyperkinesis; convulsions; sleep disorders; obsessions; panic disorder; phobias; reactive psychosis; vegetative lability, hypochondriacal-sensopathic syndrome; temporal and myoclonic epilepsy and epileptic status; stiff muscles; Premedication - as part of an initial anesthesia; as a component of complex therapy for abstinent and toxicomanic syndrome and schizophrenia; prevention of states of fear and emotional stress.

    V.F00-F09.F00 *   Dementia in Alzheimer's disease (G30 .- +)

    V.F00-F09.F03   Dementia, unspecified

    V.F00-F09.F05   Delirium not caused by alcohol or other psychoactive substances

    V.F00-F09.F07.2   Postcontasia syndrome

    V.F10-F19.F11.3   Mental and behavioral disorders caused by the use of opioids - withdrawal symptoms

    V.F20-F29.F20   Schizophrenia

    V.F20-F29.F23   Acute and transient psychotic disorders

    V.F20-F29.F25   Schizoaffective disorder

    V.F30-F39.F30   Manic episode

    V.F30-F39.F32   Depressive episode

    V.F40-F48.F40.0   Agoraphobia

    V.F40-F48.F40.8   Other phobic anxiety disorders

    V.F40-F48.F41.0   Panic disorder [episodic paroxysmal anxiety]

    V.F40-F48.F41.1   Generalized anxiety disorder

    V.F40-F48.F42   Obsessive-compulsive disorder

    V.F40-F48.F43.0   Acute stress reaction

    V.F40-F48.F43.1   Post-Traumatic Stress Disorder

    V.F40-F48.F43.2   Disorder of adaptive reactions

    V.F40-F48.F44   Dissociative [conversion] disorders

    V.F40-F48.F45   Somatoform disorders

    V.F40-F48.F45.2   Hypochondriacal disorder

    V.F40-F48.F48   Other neurotic disorders

    V.F50-F59.F51.0   Insomnia inorganic etiology

    V.F60-F69.F60   Specific personality disorders

    V.F60-F69.F60.2   Dissocial personality disorder

    V.F60-F69.F60.3   Emotionally unstable personality disorder

    V.F60-F69.F63   Disorders of habits and drives

    V.F70-F79.F79   Mental retardation, unspecified

    V.F90-F98.F95   Tiki

    VI.G40-G47.G40   Epilepsy

    VI.G40-G47.G41   Epileptic status

    VI.G40-G47.G47.0   Disturbances of falling asleep and maintaining sleep [insomnia]

    XVIII.R25-R29.R25.2   Cramp and spasm

    XVIII.R40-R46.R45.0   Nervousness

    XVIII.R40-R46.R45.4   Irritability and anger

    Contraindications:

    Severe liver and kidney disease; atmarked myasthenia gravis; poisoning with tranquilizers, neuroleptics, sleeping pills, narcotic drugs, alcohol; pregnancy and breastfeeding; angle-closure glaucoma; individual intolerance.

    Carefully:No data.
    Pregnancy and lactation:

    Category of recommendations Food and Drug Administration (US Food and Drug Administration) not determined. Use the drug during pregnancy and during breastfeeding is not recommended.

    Dosing and Administration:

    Neurotic, neurotic, psychopathic, psychopathic and other conditions (irritability, anxiety, nervous tension, emotional lability).

    The initial dose is 0.5-1 mg 2-3 times a day. After 2-4 days, taking into account the effectiveness and tolerability, the dose can be increased to 4-6 mg per day.

    Reactive psychoses and senesto-hypochondriacal disorders (including those resistant to the action of other anxiolytic drugs (tranquilizers)).

    The initial dose is 0.5-1 mg (0.5-1 ml 0.1% solution), the average daily dose is 3-5 mg, in severe cases - up to 7-9 mg.

    With severe agitation, fear, anxiety, treatment starts with a dose of 3 mg per day, rapidly increasing the dose to obtain a therapeutic effect.

    With obsessive-compulsive disorder and insomnia inside, 0.25-0.5 mg for 20-30 minutes before sleep.

    An abstinence syndrome (alcoholism, toxicomania) - inside, 2-5 mg per day, intramuscularly, 0.5 mg 1-2 times a day.

    Epileptic status and epileptic seizures (of various etiologies) - inside, 2-10 mg per day.

    Temporal and myoclonic epilepsy - inside, 2-10 mg per day.

    In extreme conditions, as a means to alleviate the feelings of fear and emotional stress, and in schizophrenia with increased sensitivity to antipsychotic drugs (including the febrile form): the initial dose is 0.5-1 mg (0.5-1 ml 0, 1% solution), the average daily dose - 3-5 mg, in severe cases - up to 7-9 mg.

    The productive symptomatology of psychotic genesis (acute delusional, hallucinatory, affective disorders) practically does not affect, rarely a decrease in affective tension, delusional disorders.

    Spasm of skeletal musculature (as part of combined therapy caused by impaired functioning of motor neurons, including paralysis and paraplegia, athetosis, stiff man syndrome, hyperkinesia, tics, vegetative lability with paroxysms of sympathoadrenal and mixed character) - inside, 2-3 mg of 1- 2 times a day.

    In autonomic paroxysms: intramuscularly, 0.5-1 mg.

    Anesthesia (as an additional remedy, as part of a premedication to relieve anxiety and tension) - as a premedication for 1-2 days before surgery under anesthesia bromodihydrochlorophenylbenzodiazepine (0.0025 mg / kg) is greater than diazepam (0.005 mg / kg) in the severity and duration of the tranquilizing effect.

    The average daily dose is 1.5-5 mg, it is divided into 2-3 doses, usually 0.5-1 mg in the morning and in the afternoon and up to 2.5 mg at night.

    Side effects:

    Nervous system and sensory organs: muscle weakness, dizziness, headache, drowsiness, memory impairment, decreased concentration of attention, paradoxical agitation, impaired gait and coordination of movements, mydriasis.

    Digestive system: dry mouth, nausea, diarrhea.

    Allergic reactions: skin rash, itching.

    Other: violation of menstruation and urination, decreased libido, addiction, drug dependence.

    Overdose:

    When an overdose is observed marked depression of consciousness, cardiac and respiratory activity. Treatment requires hospitalization and close monitoring of breathing and cardiac activity. Specific antagonist flumazenil (intravenously 0.2 mg - if necessary up to 1 mg - on a 5% solution of glucose or 0.9% solution of sodium chloride).

    Interaction:

    Mutually enhances the simultaneous use of the effects of sleeping pills, neuroleptics, tranquilizers, anesthetic, analgesic, anticonvulsants, and alcohol.

    Special instructions:

    During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

    Instructions
    Up